ClinicalTrials.gov record
Recruiting Phase 2 Interventional

Lisocabtagene Maraleucel, Nivolumab and Ibrutinib for the Treatment of Richter's Transformation

ClinicalTrials.gov ID: NCT05672173

Public ClinicalTrials.gov record NCT05672173. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 5, 2026, 7:12 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Phase 2 Study of the Combination of Lisocabtagene Maraleucel, Nivolumab, and Ibrutinib in Richter's Transformation

Study identification

NCT ID
NCT05672173
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 2
Lead sponsor
City of Hope Medical Center
Other
Enrollment
20 participants

Conditions and interventions

Interventions

  • Biopsy Procedure
  • Biospecimen Collection Procedure
  • Bone Marrow Biopsy Procedure
  • Computed Tomography Procedure
  • Cyclophosphamide Drug
  • Fludarabine Drug
  • Ibrutinib Drug
  • Lisocabtagene Maraleucel Biological
  • Nivolumab Biological
  • Pheresis Procedure
  • Positron Emission Tomography Procedure

Procedure · Drug · Biological

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Jun 1, 2023
Primary completion
Sep 9, 2026
Completion
Sep 9, 2026
Last update posted
Dec 14, 2025

2023 – 2026

United States locations

U.S. sites
2
U.S. states
2
U.S. cities
2
Facility City State ZIP Site status
City of Hope Medical Center Duarte California 91010 Recruiting
Memorial Sloan Kettering Cancer Center New York New York 10065 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05672173, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Dec 14, 2025 · Synced May 5, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05672173 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →